{"id":199683,"title":"Considerations for the use of nirmatrelvir/ritonavir (brand name Paxlovid) to treat COVID-19 - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2025-04-19","captureTimestamp":"2025-04-19T05:22:15.538000+00:00","jobId":1,"originalUrl":"https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/guidance-documents/considerations-nirmatrelvir-ritonavir-paxlovid.html?wbdisable=true","snippet":"Considerations for the use of nirmatrelvir/ritonavir (brand name Paxlovid) to treat COVID-19 - Canada.ca Skip to main content Skip to \"About government\" Language selection Français fr / Gouvernement du Canada Search Search Canada.ca Search Menu Main Menu Jobs and the workplace…","rawSnapshotUrl":"/api/snapshots/raw/199683","browseUrl":"https://replay.healtharchive.ca/job-1/20250419052215/https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/guidance-documents/considerations-nirmatrelvir-ritonavir-paxlovid.html?wbdisable=true#ha_snapshot=199683","mimeType":"text/html","statusCode":200,"captureBackend":"browsertrix","captureFidelity":"high"}